Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 7/20 | 0.59 |
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | KMO | O15229 | 6/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78430 | 0.82 | REN (0.50) | MAPK1RENKMOHTR2AHTR2C | |
| SCHEMBL16471691 | 0.80 | REN (0.50) | MAPK1RENKMOHTR2AHTR2C | |
| SCHEMBL16458716 | 0.78 | REN (0.70) | MAPK1REN | |
| SCHEMBL3411269 | 0.77 | MAPK1 (0.47) | MAPK1RENKMOMAOAMAOB | |
| SCHEMBL3779728 | 0.76 | MAPK1 (0.44) | MAPK1RENKMO | |
| SCHEMBL3779724 | 0.76 | MAPK1 (0.44) | MAPK1RENKMO | |
| SCHEMBL91363 | 0.76 | KMO (0.58) | MAPK1RENKMOMAOAMAOB | |
| SCHEMBL3785641 | 0.76 | MAPK1 (0.46) | MAPK1RENKMOMAOAMAOB | |
| SCHEMBL3785643 | 0.76 | MAPK1 (0.46) | MAPK1RENKMOMAOAMAOB | |
| SCHEMBL3785638 | 0.76 | MAPK1 (0.46) | MAPK1RENKMOMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-12-18 | — | — | US | disclosed |
| EP-2687518-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | REN, AGTR1, AGTR2 | MAPK1 415/4885REN 1/4885KMO 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.